- Email: [email protected]
Correction for Lancet Diabetes Endocrinol 2014; 2: 464–73
Corrections
Correction for Lancet Diabetes Endocrinol 2014; 2: 464–73 Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014; 2: 464–73— Following the death of Prof Michaela Diamant in April, 2014, Dr Michael E Trautmann ([email protected]) is now listed as the corresponding author for this paper. This correction has been made to the online version as of May 29, 2014, and is correct in the print version.
www.thelancet.com/diabetes-endocrinology Vol 2 June 2014
e13
Correction for Lancet Diabetes Endocrinol 2014; 2: 464–73 Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014; 2: 464–73— Following the death of Prof Michaela Diamant in April, 2014, Dr Michael E Trautmann ([email protected]) is now listed as the corresponding author for this paper. This correction has been made to the online version as of May 29, 2014, and is correct in the print version.
www.thelancet.com/diabetes-endocrinology Vol 2 June 2014
e13